A PHASE 1/2 OPEN-LABEL, DOSE-ESCALATION AND DOSE EXPANSION STUDY TO DETERMINE A CENTRAL NERVOUS SYSTEM DOSE AND SCHEDULE OF TEPOTINIB ALONE OR IN COMBINATION WITH OTHER RELEVANT TYROSINE KINASE INHIBITORS IN ADULT PARTICIPANTS WITH MET-DRIVEN NSCLC
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Tejas Patil, MD
Study ID
Protocol Number: 21-4347
More information available at ClinicalTrials.gov: NCT04739358
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers